Compare Stocks: NBP, IRWD, NVCT, and SGMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$4.36 +3.1%	$4.13	$1.26 ▼ $5.78	$720.45M	0.2	1.49 million shs	7.69 million shs
NBP I-Mab	$1.60 -1.8%	$1.77	$1.46 ▼ $6.79	$185.04M	1.5	239,301 shs	197,530 shs
NVCT Nuvectis Pharma	$22.00 +2.9%	$21.40	$5.55 ▼ $29.27	$718.17M	-0.26	185,647 shs	880,110 shs
SGMT Sagimet Biosciences	$11.09 -0.7%	$9.33	$4.50 ▼ $11.45	$689.34M	3.45	898,921 shs	1.85 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	0.00%	+6.86%	+5.31%	+23.16%	+240.63%
NBP I-Mab	0.00%	+0.63%	-16.23%	+6.67%	+159,999,900.00%
NVCT Nuvectis Pharma	0.00%	-8.30%	-5.78%	+59.19%	+255.41%
SGMT Sagimet Biosciences	0.00%	+1.93%	+8.94%	+66.02%	+80.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$4.36 +3.1%	$4.13	$1.26 ▼ $5.78	$720.45M	0.2	1.49 million shs	7.69 million shs
NBP I-Mab	$1.60 -1.8%	$1.77	$1.46 ▼ $6.79	$185.04M	1.5	239,301 shs	197,530 shs
NVCT Nuvectis Pharma	$22.00 +2.9%	$21.40	$5.55 ▼ $29.27	$718.17M	-0.26	185,647 shs	880,110 shs
SGMT Sagimet Biosciences	$11.09 -0.7%	$9.33	$4.50 ▼ $11.45	$689.34M	3.45	898,921 shs	1.85 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	0.00%	+6.86%	+5.31%	+23.16%	+240.63%
NBP I-Mab	0.00%	+0.63%	-16.23%	+6.67%	+159,999,900.00%
NVCT Nuvectis Pharma	0.00%	-8.30%	-5.78%	+59.19%	+255.41%
SGMT Sagimet Biosciences	0.00%	+1.93%	+8.94%	+66.02%	+80.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	42.97% Upside
NBP I-Mab	2.00	Hold	$9.00	462.50% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	64.77% Upside
SGMT Sagimet Biosciences	2.73	Moderate Buy	$27.96	152.11% Upside

Current Analyst Ratings Breakdown

Latest NBP, IRWD, NVCT, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/9/2026	SGMT Sagimet Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $18.00
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/27/2026	NBP I-Mab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRWD Ironwood Pharmaceuticals	$296.15M	2.43	$0.26 per share	16.94	($1.61) per share	-2.71
NBP I-Mab	$3.89M	47.57	N/A	N/A	$2.00 per share	0.80
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
SGMT Sagimet Biosciences	$2M	344.68	N/A	N/A	$3.42 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.66	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
NBP I-Mab	-$46.27M	-$0.36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)

Latest NBP, IRWD, NVCT, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	NBP I-Mab	N/A	-$0.1610	N/A	-$0.1610	N/A	N/A
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBP I-Mab	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
NBP I-Mab	N/A	7.64	8.09
NVCT Nuvectis Pharma	N/A	1.68	1.68
SGMT Sagimet Biosciences	N/A	45.03	45.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRWD Ironwood Pharmaceuticals	N/A
NBP I-Mab	38.38%
NVCT Nuvectis Pharma	96.77%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
IRWD Ironwood Pharmaceuticals	9.30%
NBP I-Mab	22.10%
NVCT Nuvectis Pharma	28.55%
SGMT Sagimet Biosciences	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRWD Ironwood Pharmaceuticals	100	165.24 million	149.87 million	Optionable
NBP I-Mab	30	115.65 million	90.09 million	N/A
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
SGMT Sagimet Biosciences	16	62.16 million	55.01 million	Optionable

NBP, IRWD, NVCT, and SGMT Headlines

Recent News About These Companies

Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Cantor Fitzgerald

September 12, 2026 | americanbankingnews.com

Sagimet Biosciences (NASDAQ:SGMT) Reaches New 1-Year High - Here's What Happened

September 11, 2026 | americanbankingnews.com

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 4.1% - Time to Buy?

September 10, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Upgraded at Cantor Fitzgerald

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $1.55 Million in Sagimet Biosciences Inc. $SGMT

September 10, 2026 | marketbeat.com

Cantor Fitzgerald initiates coverage of Sagimet Biosciences at overweight

September 9, 2026 | msn.com

Barclays upgrades Sagimet Biosciences to overweight from equal-weight

September 9, 2026 | msn.com

Sagimet Biosciences (NASDAQ:SGMT) Hits New 52-Week High - Here's Why

September 9, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys Shares of 403,545 Sagimet Biosciences Inc. $SGMT

September 5, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Sets New 1-Year High - Should You Buy?

September 3, 2026 | marketbeat.com

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | marketbeat.com

Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright

August 25, 2026 | marketbeat.com

Sagimet Biosciences Announces AURORA Phase 3 Acne Trial on Track to Begin Enrollment in Q4 2026

August 25, 2026 | quiverquant.comQ

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

August 25, 2026 | globenewswire.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | markets.businessinsider.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | globenewswire.com

FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study

August 14, 2026 | kalkinemedia.comK

Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial

August 13, 2026 | finance.yahoo.com

Sagimet higher on FDA clearance of late-stage acne trial

August 13, 2026 | msn.com

Sagimet Biosciences Inc.: Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

August 13, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP, IRWD, NVCT, and SGMT Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.36 +0.13 (+3.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.35 -0.01 (-0.23%)

As of 09/18/2026 07:53 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

I-Mab NASDAQ:NBP

$1.60 -0.03 (-1.84%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.65 +0.05 (+3.37%)

As of 09/18/2026 07:53 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Nuvectis Pharma NASDAQ:NVCT

$22.00 +0.62 (+2.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.15 +0.15 (+0.66%)

As of 09/18/2026 07:44 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Sagimet Biosciences NASDAQ:SGMT

$11.09 -0.08 (-0.72%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.05 -0.04 (-0.36%)

As of 09/18/2026 07:51 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBP, IRWD, NVCT, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBP, IRWD, NVCT, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBP, IRWD, NVCT, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP, IRWD, NVCT, and SGMT Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

I-Mab NASDAQ:NBP

Nuvectis Pharma NASDAQ:NVCT

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBP, IRWD, NVCT, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBP, IRWD, NVCT, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBP, IRWD, NVCT, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP, IRWD, NVCT, and SGMT Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

I-Mab NASDAQ:NBP

Nuvectis Pharma NASDAQ:NVCT

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools